

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/578,402-Conf. #3013
Filing Date	November 21, 2006
First Named Inventor	Laurie H. GLIMCHER
Art Unit	1633
Examiner Name	Kevin K. HILL
Attorney Docket Number	HUI-045CP2US

Sheet	1	of	14
-------	---	----	----

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-04/060304-A2	07-22-2004	Sagres Discovery, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Express Mail Label No. EM 192977662 US Dated: June 11, 2009

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	2	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Affolter, <i>et al.</i> , "Nuclear interpretation of Dpp signaling in <i>Drosophila</i> ," <i>EMBO J.</i> , Vol. 20(13):3298-305 (2001)	
	C2	Allen, <i>et al.</i> , "Developmental anomalies and neoplasia in animals and cells deficient in the large zinc finger protein KRC," <i>Genes Chromosomes Cancer</i> , Vol. 35(4):287-98 (2002)	
	C3	Allen, <i>et al.</i> , "Downregulation of KRC induces proliferation, anchorage independence, and mitotic cell death in HeLa cells," <i>Exp Cell Res.</i> , Vol. 260(2):346-56 (2000)	
	C4	Allen, Carl E. <i>et al.</i> , "KRC controls cell growth by regulating the transcription of c-myc," Presented at the American Society of Biochemistry and Molecular Biology Annual Meeting, Washington, D.C., pg. A1391, Abstract No. 473 (1998)	
	C5	Allen, <i>et al.</i> , "The kappa B transcriptional enhancer motif and signal sequences of V(D)J recombination are targets for the zinc finger protein HIVP3/KRC: a site selection amplification binding study," <i>BMC Immunol.</i> , Vol. 22;3(1):10 (2002)	
	C6	Alliston, Tamara <i>et al.</i> , "TGF- β -induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation," <i>The EMBO Journal</i> , Vol. 20(9):2254-2272 (2001)	
	C7	Anders, Hans-Joachim <i>et al.</i> , "MURINE Models of Renal Disease: Possibilities and Problems in Studies Using Mutant Mice," <i>Exp. Nephrol.</i> , Vol. 8:181-193 (2000)	
	C8	Angel P, <i>et al.</i> , "Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor," <i>Cell</i> , Vol. 49(6):729-39 (1987)	
	C9	Arch, <i>et al.</i> , "Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death," <i>Genes Dev.</i> , Vol. 12(18):2821-30 (1998)	
	C10	Arias, <i>et al.</i> , "Activation of cAMP and mitogen responsive genes relies on a common nuclear factor," <i>Nature</i> , Vol. 370(6486):226-9 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	3	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C11	Arora, <i>et al.</i> , "The Drosophila schnurri gene acts in the Dpp/TGF beta signaling pathway and encodes a transcription factor homologous to the human MBP family," <i>Cell</i> , Vol. 81(5):781-90 (1995)	
	C12	Bachmeyer, <i>et al.</i> , "Regulation by phosphorylation of the zinc finger protein KRC that binds the kappaB motif and V(D)J recombination signal sequences," <i>Nucleic Acids Res.</i> , Vol. 27(2):643-8 (1999)	
	C13	Behre, <i>et al.</i> , "C-Jun is a JNK-independent coactivator of the PU.1 transcription factor," <i>J. Biol. Chem.</i> , Vol. 274(8):4939-46 (1999)	
	C14	Behrens, <i>et al.</i> , "Jun N-terminal kinase 2 modulates thymocyte apoptosis and T cell activation through c-Jun and nuclear factor of activated T cell (NF-AT)," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 98(4):1769-74 (2001)	
	C15	Bianchi, <i>et al.</i> , "Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity," <i>Nature</i> , Vol. 404(6778):617-21 (2000)	
	C16	Binetruy, <i>et al.</i> , "Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain," <i>Nature</i> , Vol. 351(6322):122-7 (1991)	
	C17	Bishop, Jo, "Chromosomal insertion of foreign DNA," <i>Reprod. Nutr. Dev.</i> , Vol. 36:607-618 (1996)	
	C18	Blokzijl, Andries <i>et al.</i> , "Physical and Functional Interaction between GATA-3 and Smad3 Allows TGF- β Regulation of GATA Target Genes," <i>Current Biology</i> , Vol. 12:35-45 (2002)	
	C19	Borden, <i>et al.</i> , "The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML," <i>EMBO J.</i> , Vol. 14(7):1532-41 (1995)	
	C20	Bork, Peer, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Research</i> , Vol. 10:398-400 (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	4	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	Cameron, Ewan R., "Recent Advances in Transgenic Technology," <i>Molecular Biotechnology</i> , Vol. 7:253-265 (1997)	
	C22	Cao, <i>et al.</i> , "TRAF6 is a signal transducer for interleukin-1," <i>Nature</i> , Vol. 383(6599):443-6 (1996)	
	C23	Castellanos, <i>et al.</i> , "Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1," <i>J. Immunol.</i> , Vol. 159(11):5463-73 (1997)	
	C24	Claret, <i>et al.</i> , "A new group of conserved coactivators that increase the specificity of AP-1 transcription factors," <i>Nature</i> , Vol. 383(6599):453-7 (1996)	
	C25	Cleland, Jeffrey L. <i>et al.</i> , "Emerging protein delivery methods," <i>Current Opinion in Biotechnology</i> , Vol. 12:212-219 (2001)	
	C26	Cohn, <i>et al.</i> , "Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA as functional elements of the metastasis-associated mts1/S100A4 gene intronic enhancer," <i>Nucleic Acids Res.</i> , Vol. 29(16):3335-46 (2001)	
	C27	Daga, Andrea <i>et al.</i> , "Patterning of cells in the <i>Drosophila</i> eye by Lozenge, which shares homologous domains with AML1," <i>Genes & Development</i> , Vol. 10:1194-1205 (1996)	
	C28	Dai, <i>et al.</i> , "The zinc finger protein schnurri acts as a Smad partner in mediating the transcriptional response to decapentaplegic," <i>Dev. Biol.</i> , Vol. 227(2):373-87 (2000)	
	C29	Deng, <i>et al.</i> , "c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK," <i>Nature</i> , Vol. 371(6493):171-5 (1994)	
	C30	Denning, C. <i>et al.</i> , "Deletion of the $\alpha(1,3)$ galactosyl transferase (GGTA1) gene and the prion protein (<i>PrP</i>) gene in sheep," <i>Nature Biotechnology</i> , Vol. 19:559-562 (2001)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	5	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C31	Deonarain, Mahendra P., "Ligand-targeted receptor-mediated vectors for gene delivery," <i>Exp. Opin. Ther. Patents</i> , Vol. 8(1):53-69 (1998)		
	C32	Derynck, Rik et al., "Smads: Transcriptional Activators of TGF- β Responses," <i>Cell</i> , Vol. 95:737-740 (1998)		
	C33	Doerks, Tobias et al., "Protein annotation: detective work for function prediction," <i>TIG</i> , Vol. 14(6):248-250 (1998)		
	C34	Dong, et al., "JNK is required for effector T-cell function but not for T-cell activation," <i>Nature</i> , Vol. 405(6782):91-4 (2000)		
	C35	Dumitru, et al., "TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway," <i>Cell</i> , Vol. 103(7):1071-83 (2000)		
	C36	Durand, et al., "A 275 basepair fragment at the 5' end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor," <i>J. Exp. Med.</i> , Vol. 165(2):395-407 (1987)		
	C37	Eck, Stephen L. et al., "Gene-Based Therapy," <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , Ninth Edition, McGraw-Hill, Chpt. 5, pgs. 77-101 (1996)		
	C38	Gerlai, Robert, "Gene-targeting studies of mammalian behavior: is is the mutation or the background genotype," <i>Trends Neurosci.</i> , Vol. 19:177-181 (1996)		
	C39	Ghosh, et al., "NF-KappaB and Rel Proteins: Evolutionarily conserved mediators of immune responses," <i>Annu. Rev. Immunol.</i> , Vol. 16:226-260 (1998)		
	C40	Glimcher, Laurie H. et al., "Control of Postnatal Bone Mass by the Zinc Finger Adapter Protein Schnurri-3," <i>Ann. N.Y. Acad. Sci.</i> , Vol. 1116:174-181 (2007)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	6	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C41	Górecki, Dariusz C., "Prospects and problems of gene therapy: an update," <i>Expert Opinion Emerging Drugs</i> , Vol. 6(2):187-198 (2001)		
	C42	Grieder, <i>et al.</i> , "Schnurri is required for Drosophila Dpp signaling and encodes a zinc finger protein similar to the mammalian transcription factor PRDII-BF1," <i>Cell</i> , Vol. 81(5):791-800 (1995)		
	C43	Hicar, <i>et al.</i> , "Embryonic expression and regulation of the large zinc finger protein KRC," <i>Genesis</i> , Vol. 33(1):8-20 (2002)		
	C44	Hicar, <i>et al.</i> , "Structure of the human zinc finger protein HIVEP3: molecular cloning, expression, exon-intron structure, and comparison with paralogous genes HIVEP1 and HIVEP2," <i>Genomics</i> , Vol. 71(1):89-100 (2001)		
	C45	Himes, <i>et al.</i> , "High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters," <i>Immunity</i> , Vol. 5(5):479-89 (1996)		
	C46*	Hjelmsoe, <i>et al.</i> , "The kappaB and V(D)J recombination signal sequence binding protein KRC regulates transcription of the mouse metastasis-associated gene S100A4/mts1," <i>J. Biol. Chem.</i> , Vol. 275(2):913-20 (2000)		
	C47	Houdebine, Louis-Marie, "Production of pharmaceutical proteins from transgenic animals," <i>Journal of Biotechnology</i> , Vol. 34:269-287 (1994)		
	C48	Humpherys, David et al., "Epigenetic Instability in ES Cells and Cloned Mice," <i>Science</i> , Vol. 293:95-97 (2001)		
	C49	Ip, <i>et al.</i> , "Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development," <i>Curr. Opin. Cell Biol.</i> , Vol. 10(2):205-19 (1998)		
	C50	Isakov, <i>et al.</i> , "Protein kinase C(theta) in T cell activation," <i>Annu. Rev. Immunol.</i> , Vol. 20:761-94 (2002)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	7	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C51	Jain, <i>et al.</i> , "Nuclear factor of activated T cells contains Fos and Jun," <i>Nature</i> , Vol. 356(6372):801-4 (1992)	
	C52	Jain, <i>et al.</i> , "Transcriptional regulation of the IL-2 gene," <i>Curr. Opin. Immunol.</i> , Vol. 7(3):333-42 (1995)	
	C53	Jochum, <i>et al.</i> , "AP-1 in mouse development and tumorigenesis," <i>Oncogene</i> , Vol. 20(19):2401-12 (2001)	
	C54	Jones, Dallas C. et al., "Regulation of Adult Bone Mass by the Zinc Finger Adapter Protein Schnurri-3," <i>Science</i> , Vol. 312:1223-1227 (2006)	
	C55	Jones, Dallas C. et al., "Schnurri-3: A Key Regulator of Postnatal Skeletal Remodeling," <i>Adv. Exp. Med. Biol.</i> , Osteoimmunology, Interactions of the Immune and Skeletal Systems, Yongwon Choi, Ed., Springer, Volume 602, Chapter 1, pgs. 1-13 (2007)	
	C56	Jones, Dallas C. et al., "Schnurri-3 is an essential regulator of osteoblast function and adult bone mass," <i>Ann. Rheum. Dis</i> , Vol. 66(Suppl. III):iii49-iii51 (2007)	
	C57	Kamei, <i>et al.</i> , "A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors," <i>Cell</i> , Vol. 85(3):403-14 (1996)	
	C58	Kappel, Catherine A. et al., "Regulating gene expression in transgenic animals," <i>Current Opinion in Biotechnology</i> , Vol. 3:548-553 (1992)	
	C59	Karin, <i>et al.</i> , "AP-1 function and regulation," <i>Curr. Opin. Cell Biol.</i> , Vol. 9(2):240-6 (1997)	
	C60	Karin M., "The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival," <i>Cancer J. Sci. Am.</i> , Vol. 4 Suppl 1:S92-9 (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	8	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C61	Kuroiwa, Yoshimi et al., "Sequential targeting of the genes encoding immunoglobulin-μ and prion protein in cattle," <i>Nature Genetics</i> , Vol. 36(7):775-780 (2004)		
	C62	Lee, <i>et al.</i> , "Activating protein-1, nuclear factor-kappaB, and serum response factor as novel target molecules of the cancer-amplified transcription coactivator ASC-2," <i>Mol. Endocrinol.</i> , Vol. 14(6):915-25 (2000)		
	C63	Lee, <i>et al.</i> , "Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits," <i>J. Biol. Chem.</i> , Vol. 273(27):16651-4 (1998)		
	C64	Lee, <i>et al.</i> , "TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival," <i>Immunity</i> , Vol. 7(5):703-13 (1997)		
	C65	Leppa, <i>et al.</i> , "Diverse functions of JNK signaling and c-Jun in stress response and apoptosis," <i>Oncogene</i> , Vol. 18(45):6158-62 (1999)		
	C66	Liberati, <i>et al.</i> , "Smads bind directly to the Jun family of AP-1 transcription factors," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 96(9):4844-9 (1999)		
	C67	Lindsten, <i>et al.</i> , "Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway," <i>Science</i> , Vol. 244(4902):339-43 (1989)		
	C68	Lund, Anders H. et al., "RUNX: A trilogy of cancer genes," <i>Cancer Cell</i> , Vol. 1:213-215 (2002)		
	C69	Lutterbach, B. et al., "Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation," <i>Gene</i> , Vol. 245:223-235 (2000)		
	C70	Macian, <i>et al.</i> , "Transcriptional mechanisms underlying lymphocyte tolerance," <i>Cell</i> , Vol. 109(6):719-31 (2002)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	9	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C71	Mak, <i>et al.</i> , "KRC transcripts: identification of an unusual alternative splicing event," <i>Immunogenetics</i> , Vol. 48(1):32-9 (1998)	
	C72	Mak, <i>et al.</i> , "The V(D)J recombination signal sequence and kappa B binding protein R _c binds DNA as dimers and forms multimeric structures with its DNA ligands," <i>Nucleic Acids Res.</i> , Vol. 22(3):383-90 (1994)	
	C73	Massagué, Joan <i>et al.</i> , "Transcriptional control by the TGF- β /Smad signaling system," <i>The EMBO Journal</i> , Vol. 19(8):1745-1754 (2000)	
	C74	Matunis, <i>et al.</i> , "Punt and schnurri regulate a somatically derived signal that restricts proliferation of committed progenitors in the germline," <i>Development</i> , Vol. 124(21):4383-91 (1997)	
	C75	Mondino, <i>et al.</i> , "Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells," <i>J. Immunol.</i> , Vol. 157(5):2048-57 (1996)	
	C76	Moreadith, Randall Wade <i>et al.</i> , "Gene targeting in embryonic stem cells: the new physiology and metabolism," <i>J. Mol. Med.</i> , Vol. 75:208-216 (1997)	
	C77	Moreau, <i>et al.</i> , "Bone-specific expression of the alpha chain of the nascent polypeptide-associated complex, a coactivator potentiating c-Jun-mediated transcription," <i>Mol. Cell Biol.</i> , Vol. 18(3):1312-21 (1998)	
	C78	Mullins, John J. <i>et al.</i> , "Transgenesis in Nonmurine Species," <i>Hypertension</i> , Vol. 22(4):630-633 (1993)	
	C79	Mullins, Linda J. <i>et al.</i> , "Molecular Medicine in Genetically Engineered Animals," <i>J. Clin. Invest.</i> , Vol. 97(7):1557-1560 (1996)	
	C80	Murphy, <i>et al.</i> , "Molecular interpretation of ERK signal duration by immediate early gene products," <i>Nat. Cell Biol.</i> , Vol. 4(8):556-64 (2002)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	10	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C81	Nakano, <i>et al.</i> , "TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor," <i>J. Biol. Chem.</i> , Vol. 271(25):14661-4 (1996)	
	C82	Ngo, J. Thomas et al., "Computational Complexity Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Chpt. 14, pgs. 491-495 (1994)	
	C83	Oukka, <i>et al.</i> , "A mammalian homolog of Drosophila schnurri, KRC, regulates TNF receptor-driven responses and interacts with TRAF2," <i>Mol. Cell.</i> , Vol. 9(1):121-31 (2002)	
	C84	Oukka, Mohamed et al., "Schnurri-3 (KRC) Interacts with c-Jun to Regulate the IL-2 Gene in T Cells," <i>J. Exp. Med.</i> , Vol. 199(1):15-24 (2004)	
	C85	Pearson, Helen, "Surviving a knockout blow," <i>Nature</i> , Vol. 415:8-9 (2002)	
	C86	Pessah, <i>et al.</i> , "C-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity," <i>J. Biol. Chem.</i> , Vol. 277(32):29094-100 (2002)	
	C87	Polejaeva, I.A. et al., "New Advances in Somatic Cell Nuclear Transfer: Application in Transgenesis," <i>Theriogenology</i> , Vol. 53:117-126 (2000)	
	C88	Rayter, <i>et al.</i> , "p21ras mediates control of IL-2 gene promoter function in T cell activation," <i>EMBO J.</i> , Vol. 11(12):4549-56 (1992)	
	C89	Rooney, <i>et al.</i> , "Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene," <i>Immunity</i> , Vol. 2(5):473-83 (1995)	
	C90	Rothe, <i>et al.</i> , "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor," <i>Cell</i> , Vol. 78(4):681-92 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	11	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C91	Rudinger J., "Characteristics of the amino acids as components of a peptide hormone sequence," <i>Peptide Hormones</i> , University Park Press, J.A. Parsons, Ed., Chpt. 1, pgs. 1-7 (1976)		
	C92	Rülicke, T. et al., "Germ line transformation of mammals by pronuclear microinjection," <i>Experimental Physiology</i> , Vol. 85(6):589-601 (2000)		
	C93	Schalkwyk, L.C. et al., "Interpretation of knockout experiments: the congenic footprint," <i>Genes, Brain and Behavior</i> , Vol. 6:299-303 (2007)		
	C94	Shi, Meng-Jiao et al., "CBF α 3 (AML2) Is Induced by TGF- β 1 to Bind and Activate the Mouse Germline Ig α Promoter," <i>The Journal of Immunology</i> , Vol. 161:6751-6760 (1998)		
	C95	Sigmund, Curt D., "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?" <i>Arterioscler. Thromb. Vasc. Biol.</i> , Vol. 20:1425-1429 (2000)		
	C96	Skolnick, Jeffrey et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>TibTech</i> , Vol. 18:34-39 (2000)		
	C97	Smith, Temple F. et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <i>Nature Biotechnology</i> , Vol. 15:1222-1223 (1997)		
	C98	Staehling-Hampton, et al., "A Drosophila protein related to the human zinc finger transcription factor PRDII/MBPI/HIV-EP1 is required for dpp signaling," <i>Development</i> , Vol. 121(10):3393-403 (1995)		
	C99	Sun, et al., "PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes," <i>Nature</i> , Vol. 404(6776):402-7 (2000)		
	C100	Szabo, et al., "A novel transcription factor, T-bet, directs Th1 lineage commitment," <i>Cell</i> , Vol. 100(6):655-69 (2000)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	12	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C101	Takagi, <i>et al.</i> , "Murine Schnurri-2 is required for positive selection of thymocytes," <i>Nat. Immunol.</i> , Vol. 2(11):1048-53 (2001)	
	C102	Torres-Vazquez, <i>et al.</i> , "The transcription factor Schnurri plays a dual role in mediating Dpp signaling during embryogenesis," <i>Development</i> , Vol. 128(9):1657-70 (2001)	
	C103	Torres-Vazquez, <i>et al.</i> , "Schnurri is required for dpp-dependent patterning of the Drosophila wing," <i>Dev. Biol.</i> , Vol. 227(2):388-402 (2000)	
	C104	Udagawa, <i>et al.</i> , "Schnurri interacts with Mad in a Dpp-dependent manner," <i>Genes Cells</i> , Vol. 5(5):359-69 (2000)	
	C105	Ullman, <i>et al.</i> , "Jun family members are controlled by a calcium-regulated, cyclosporin A-sensitive signaling pathway in activated T lymphocytes," <i>Genes Dev.</i> , Vol. 7(2):188-96 (1993)	
	C106	Verma, Inder M. <i>et al.</i> , "Gene therapy - promises, problems and prospects," <i>Nature</i> , Vol. 389:239-242 (1997)	
	C107	Wajant, <i>et al.</i> , "TNF receptor associated factors in cytokine signaling," <i>Cytokine Growth Factor Rev.</i> , Vol. 10(1):15-26 (1999)	
	C108	Wall, R.J. <i>et al.</i> , "Transgenic Dairy Cattle: Genetic Engineering on a Large Scale," <i>J. Dairy Sci.</i> , Vol. 80(9):2213-2224 (1997)	
	C109	Wall, R.J., "Transgenic Livestock: Progress and Prospects for the Future," <i>Theriogenology</i> , Vol. 45:57-68 (1996)	
	C110	Wallach, <i>et al.</i> , "Tumor necrosis factor receptor and Fas signaling mechanisms," <i>Annu. Rev. Immunol.</i> , Vol. 17:331-67 (1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	13	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C111	Weiss, et al., "Regulation of c-Jun NH(2)-terminal kinase (Jnk) gene expression during T cell activation," <i>J. Exp. Med.</i> , Vol. 191(1):139-46 (2000)		
	C112	Wells, James A. et al., "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> , Vol. 29(37):8509-8517 (1990)		
	C113	Wu, et al., "IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival," <i>Science</i> , Vol. 281(5379):998-1001 (1998)		
	C114	Wu, Lai-Chu et al., "The DNA-binding activity ability of HIVP3/KRC decreases upon activation of V(D)J recombination," <i>Immunogenetics</i> , Vol. 53:564-571 (2001)		
	C115	Wu, et al., "The mouse DNA binding protein Rc for the kappa B motif of transcription and for the V(D)J recombination signal sequences contains composite DNA-protein interaction domains and belongs to a new family of large transcriptional proteins," <i>Genomics</i> , Vol. 35(3):415-24 (1996)		
	C116	Wu, "ZAS: C2H2 zinc finger proteins involved in growth and development," <i>Gene Expr.</i> , Vol. 10(4):137-52 (2002)		
	C117	Yanagimachi, R., "Cloning: experience from the mouse and other animals," <i>Molecular and Cellular Endocrinology</i> , Vol. 187:241-248 (2002)		
	C118	Yeh, et al., "Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice," <i>Immunity</i> , Vol. 7(5):715-25 (1997)		
	C119	Zhang, et al., "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription," <i>Nature</i> , Vol. 394(6696):909-13 (1998)		
	C120	Zhang, Ying et al., "Transcriptional Regulation of the Transforming Growth Factor-beta-inducible Mouse Germ Line Ig alpha Constant Region Gene by Functional Cooperation of Smad, CREB, and AML, Family Members," <i>The Journal of Biological Chemistry</i> , Vol. 275(22):16979-16985 (2000)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/578,402-Conf. #3013
				Filing Date	November 21, 2006
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1633
				Examiner Name	Kevin K. HILL
Sheet	14	of	14	Attorney Docket Number	HUI-045CP2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C121	International Search Report for Application No. PCT/US04/36641, dated May 18, 2005	
	C122	International Preliminary Report on Patentability for Application No. PCT/US2004/036641, dated May 8, 2006	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.